Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 7/20 | 0.64 |
| ▸ | DBF4 | Q9UBU7 | 7/20 | 0.64 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | RARA | P10276 | 1/20 | 0.55 |
| ▸ | RARB | P10826 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887195 | 0.88 | L3MBTL1 (0.62) | CDC7DBF4TRPM8L3MBTL1ALDH1A1 | |
| SCHEMBL22939973 | 0.88 | L3MBTL1 (0.62) | CDC7DBF4TRPM8L3MBTL1ALDH1A1 | |
| SCHEMBL12049696 | 0.87 | L3MBTL1 (0.58) | CDC7DBF4TRPM8L3MBTL1ALDH1A1 | |
| SCHEMBL12049565 | 0.87 | L3MBTL1 (0.64) | CDC7DBF4TRPM8L3MBTL1ALDH1A1 | |
| SCHEMBL27931296 | 0.86 | L3MBTL1 (0.60) | CDC7DBF4TRPM8L3MBTL1ALDH1A1 | |
| SCHEMBL13437316 | 0.86 | L3MBTL1 (0.60) | CDC7DBF4TRPM8L3MBTL1ALDH1A1 | |
| SCHEMBL2880217 | 0.85 | RARA (0.66) | CDC7DBF4TRPM8L3MBTL1ALDH1A1 | |
| SCHEMBL20785682 | 0.83 | TRPM8 (0.63) | CDC7DBF4TRPM8L3MBTL1ALDH1A1 | |
| SCHEMBL2483841 | 0.83 | L3MBTL1 (0.59) | CDC7DBF4TRPM8L3MBTL1ALDH1A1 | |
| SCHEMBL12049695 | 0.82 | TRPM8 (0.61) | CDC7DBF4TRPM8L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC., | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306609-A1 | THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | CDC7 1455/4885DBF4 4100/4885TRPM8 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.